Top

International Ophthalmology

Published in:

Open Access 01-12-2024 | Gout | Review

Correlation between gout and dry eye disease

Authors: Tongtong Chen, Jiaqi Chen, Cong Zhao, Xiang Li

Published in: International Ophthalmology | Issue 1/2024

Abstract

Background

Gout is a common form of inflammatory arthritis that can cause a number of serious complications. Complications are common in patients with gout and complicate their management and disease outcome. The recent literature has reported that an increasing number of gout patients are presenting with dry eye symptoms. However, until now, the link between gout and dry eye disease has not been clearly defined. (It is unclear whether the two conditions simply co-exist, whether there are common risk factors, or whether dry eye disease is a complication of gout.)

Methods

A thorough literature search was conducted in the PubMed database to summarize the most recent information on the correlation between gout and dry eye disease and to explore the potential relationship between the pathogenesis of the two. (Objective: Therefore, in this paper, we review the recent literature on the correlation between gout and dry eye disease and explore the potential association between the pathogenesis of both.)

Results

Studies in the last five years have shown a correlation between gout and dry eye, i.e., gout is associated with an increased risk of dry eye. The NLRP3-IL-1β signaling pathway may be a potential mechanism for the combination of gout and dry eye disease; factors such as high blood uric acid and xanthine oxidase activation in gout patients may aggravate the development of dry eye disease; reducing the use of visual display terminals; reducing or abstaining from alcohol consumption; and moderate coffee intake may effectively prevent gout and dry eye disease.

Conclusions

It is an undisputed fact that many gout patients present with dry eye manifestations that seriously affect the quality of life of gout patients, and early detection and treatment of dry eye in gout patients are crucial.

Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatm ent patterns and risk factors. Nat Rev Rheumatol 16:380–390. https://doi.org/10.1038/s41584-020-0441-1CrossRefPubMed

Dalbeth N, Merriman TR, Stamp LK (2016) Gout. Lancet 388:2039–2052. https://doi.org/10.1016/S0140-6736(16)00346-9CrossRefPubMed

Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout. Lancet 397:1843–1855. https://doi.org/10.1016/S0140-6736(21)00569-9CrossRefPubMed

Lin J, Zhao GQ, Che CY, Yang SS, Wang Q, Li CG (2013) Characteristics of ocular abnormalities in gout patients. Int J Ophthalmol 6:307–311. https://doi.org/10.3980/j.issn.2222-3959.2013.03.09CrossRefPubMedPubMedCentral

Morris WR, Fleming JC (2003) Gouty tophus at the lateral canthus. Arch Ophthalmol 121:1195–1197. https://doi.org/10.1001/archopht.121.8.1195CrossRefPubMed

Lo WR, Broocker G, Grossniklaus HE (2005) Histopathologic examination of conjunctival tophi in gouty arthritis. Am J Ophthalmol 140:1152–1154. https://doi.org/10.1016/j.ajo.2005.07.023CrossRefPubMed

Coassin M, Piovanetti O, Stark WJ, Green WR (2006) Urate deposition in the iris and anterior chamber. Ophthalmology 113:462–465. https://doi.org/10.1016/j.ophtha.2005.11.012CrossRefPubMed

Yazdanyar A, Rizzuti AE, Mechel E, Denisova K, Lazzaro DR (2018) Gout keratitis: a case of peripheral ulcerative keratitis secondary to gout with a review of the literature. Cornea 37:379–381. https://doi.org/10.1097/ICO.0000000000001415CrossRefPubMed

Ferry AP, Safir A, Melikian HE (1985) Ocular abnormalities in patients with gout. Ann Ophthalmol 17:632–635PubMed

10.

Luo C, Chen X, Jin H, Yao K (2017) The association between gout and cataract risk: a meta-analysis. PLoS ONE 12:e180188. https://doi.org/10.1371/journal.pone.0180188CrossRef

11.

Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F (2017) TFOS DEWS II definition and classification report. Ocular Surface 15:276–283. https://doi.org/10.1016/j.jtos.2017.05.008CrossRefPubMed

12.

Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ (2003) Prevalence and associations of dry eye syndrome in an older population: the blue mountains eye study. Clin Exp Ophthalmol 31:229–232. https://doi.org/10.1046/j.1442-9071.2003.00634.xCrossRefPubMed

13.

Moss SE, Klein R, Klein BE (2000) Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 118:1264–1268. https://doi.org/10.1001/archopht.118.9.1264CrossRefPubMed

14.

Moss SE, Klein R, Klein BE (2004) Incidence of dry eye in an older population. Arch Ophthalmol 122:369–373. https://doi.org/10.1001/archopht.122.3.369CrossRefPubMed

15.

Moss SE, Klein R, Klein BE (2008) Long-term incidence of dry eye in an older population. Optom Vis Sci 85:668–674. https://doi.org/10.1097/OPX.0b013e318181a947CrossRefPubMed

16.

Alshamrani AA, Almousa AS, Almulhim AA, Alafaleq AA, Alosaimi MB, Alqahtani AM, Almulhem AM, Alshamrani MA, Alhallafi AH, Alqahtani IZ, Alshehri AA (2017) Prevalence and risk factors of dry eye symptoms in a saudi arabian population. Mid East Afr J Ophthalmol 24:67–73. https://doi.org/10.4103/meajo.MEAJO_281_16CrossRef

17.

Lee CY, Chen HC, Sun CC, Lin HY, Lu KH, Huang JY, Yeh CB, Yang SF (2019) Gout as a risk factor for dry eye disease: a population-based cohort study. J Clin Med. https://doi.org/10.3390/jcm8010062CrossRefPubMedPubMedCentral

18.

Belviranli S, Turk HB, Oltulu P, Turk N, Mirza E, Küçük A, Aydemir H, Oltulu R (2021) Tear function alterations and conjunctival impression cytology findings in patients with gout. Eye Cont Lens-Sci Clin Pract 47:647–650. https://doi.org/10.1097/ICL.0000000000000832CrossRef

19.

Qian L, Wei W (2022) Identified risk factors for dry eye syndrome: a systematic review and meta-analysis. PLoS ONE 17:e271267. https://doi.org/10.1371/journal.pone.0271267CrossRef

20.

Lee CY, Lian IB, Jhan YN, Yang SF, Chang CK (2022) Lifestyle and symptom risk factors for dry eye disease in Asian gout population: a population-based case-control study. J Clin Med. https://doi.org/10.3390/jcm11247378CrossRefPubMedPubMedCentral

21.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen T, Janssens H, Liote F, Mallen CD, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell A, So AK, Tausche A, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2020) 2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79:31–38. https://doi.org/10.1136/annrheumdis-2019-215315CrossRefPubMed

22.

Di Giovine FS, Malawista SE, Nuki G, Duff GW (1987) Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 138:3213–3218CrossRefPubMed

23.

Ragab G, Elshahaly M, Bardin T (2017) Gout: an old disease in new perspective: a review. J Adv Res 8:495–511. https://doi.org/10.1016/j.jare.2017.04.008CrossRefPubMedPubMedCentral

24.

Zha X, Yang B, Xia G, Wang S (2022) Combination of uric acid and pro-inflammatory cytokines in discriminating patients with gout from healthy controls. J Inflamm Res 15:1413–1420. https://doi.org/10.2147/JIR.S357159CrossRefPubMedPubMedCentral

25.

Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241. https://doi.org/10.1038/nature04516ADSCrossRefPubMed

26.

Szekanecz Z, Szamosi S, Kovács GE, Kocsis E, Benkő S (2019) The NLRP3 inflammasome: interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophys 670:82–93. https://doi.org/10.1016/j.abb.2019.01.031CrossRefPubMed

27.

Wang Z, Zhang S, Xiao Y, Zhang W, Wu S, Qin T, Yue Y, Qian W, Li L (2020) NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev 2020:4063562. https://doi.org/10.1155/2020/4063562CrossRefPubMedPubMedCentral

28.

Zhou Y, Zhao M, Pu Z, Xu G, Li X (2018) Relationship between oxidative stress and inflammation in hyperuricemia: analysis based on asymptomatic young patients with primary hyperuricemia. Medicine 97:e13108CrossRefPubMedPubMedCentral

29.

Lu Y, Wu Y, Zhou X, Inomata T, Gu L, Jin X, Hong J (2022) Editorial: advances in the pathophysiology, diagnosis, and treatment of dry eye disease. Front Med. https://doi.org/10.3389/fmed.2022.925876CrossRefPubMedPubMedCentral

30.

Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC (2001) Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 42:2283–2292PubMed

31.

Yoon KC, Jeong IY, Park YG, Yang SY (2007) Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea 26:431–437. https://doi.org/10.1097/ICO.0b013e31803dcda2CrossRefPubMed

32.

Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D (1999) Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca. Curr Eye Res 19:201–211. https://doi.org/10.1076/ceyr.19.3.201.5309CrossRefPubMed

33.

Ling J, Chan BC, Tsang MS, Gao X, Leung PC, Lam CW, Hu J, Wong CK (2022) Current advances in mechanisms and treatment of dry eye disease: toward anti-inflammatory and immunomodulatory therapy and traditional Chinese medicine. Front Med. https://doi.org/10.3389/fmed.2021.815075CrossRefPubMedPubMedCentral

34.

Zheng Q, Ren Y, Reinach PS, She Y, Xiao B, Hua S, Qu J, Chen W (2014) Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye. Exp Eye Res 125:1–8. https://doi.org/10.1016/j.exer.2014.05.001CrossRefPubMed

35.

So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28. https://doi.org/10.1186/ar2143CrossRefPubMedPubMedCentral

36.

Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling KL, Sparve E, Åkerblad AC, Wikén M, So A, Pillinger MH, Terkeltaub R (2021) A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73:1533–1542. https://doi.org/10.1002/art.41699CrossRefPubMed

37.

Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, Dana R (2013) Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 131:715–723. https://doi.org/10.1001/jamaophthalmol.2013.195CrossRefPubMedPubMedCentral

38.

Wu M, Hu X, Lu T, Liu C, Lu H (2023) Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients. Immun Inflamm Dis 11:e805. https://doi.org/10.1002/iid3.805CrossRefPubMedPubMedCentral

39.

Sambursky R (2016) Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. Clin Ophthalmol 10:2337–2343. https://doi.org/10.2147/OPTH.S121256CrossRefPubMedPubMedCentral

40.

Magno MS, Utheim TP, Morthen MK, Snieder H, Jansonius NM, Hammond CJ, Vehof J (2023) The relationship between caffeine intake and dry eye disease. Cornea 42:186–193. https://doi.org/10.1097/ICO.0000000000002979CrossRefPubMed

41.

Wang M, Muntz A, Mamidi B, Wolffsohn JS, Craig JP (2021) Modifiable lifestyle risk factors for dry eye disease. Cont Lens Anterior Eye 44:101409. https://doi.org/10.1016/j.clae.2021.01.004CrossRefPubMed

42.

Shoari A, Kanavi MR, Rasaee MJ (2021) Inhibition of matrix metalloproteinase-9 for the treatment of dry eye syndrome; a review study. Exp Eye Res. https://doi.org/10.1016/j.exer.2021.108523CrossRefPubMed

43.

Smith VA, Rishmawi H, Hussein H, Easty DL (2001) Tear film MMP accumulation and corneal disease. Br J Ophthalmol 85:147–153. https://doi.org/10.1136/bjo.85.2.147CrossRefPubMedPubMedCentral

44.

Soifer M, Mousa HM, Stinnett SS, Galor A, Perez VL (2021) Matrix metalloproteinase 9 positivity predicts long term decreased tear production. Ocular Surface 19:270–274. https://doi.org/10.1016/j.jtos.2020.10.003CrossRefPubMed

45.

Sambursky R, Davitt WR, Latkany R, Tauber S, Starr C, Friedberg M, Dirks MS, McDonald M (2013) Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 131:24–28. https://doi.org/10.1001/jamaophthalmol.2013.561CrossRefPubMed

46.

Feng W, Zhong XQ, Zheng XX, Liu QP, Liu MY, Liu XB, Lin CS, Xu Q (2022) Study on the effect and mechanism of quercetin in treating gout arthritis. Int Immunopharmacol 111:109112. https://doi.org/10.1016/j.intimp.2022.109112CrossRefPubMed

47.

Nutmakul T (2022) A review on benefits of quercetin in hyperuricemia and gouty arthritis. Saudi Pharm J 30:918–926. https://doi.org/10.1016/j.jsps.2022.04.013CrossRefPubMedPubMedCentral

48.

Oh HN, Kim CE, Lee JH, Yang JW (2015) Effects of quercetin in a mouse model of experimental dry eye. Cornea 34:1130–1136. https://doi.org/10.1097/ICO.0000000000000543CrossRefPubMed

49.

Sekine M, Okamoto K, Ichida K (2021) Association of mutations identified in xanthinuria with the function and inhibition mechanism of xanthine oxidoreductase. Biomedicines. https://doi.org/10.3390/biomedicines9111723CrossRefPubMedPubMedCentral

50.

Malik N, Khatkar A, Dhiman P (2020) Computational analysis and synthesis of syringic acid derivatives as xanthine oxidase inhibitors. Med Chem 16:643–653. https://doi.org/10.2174/1573406415666191004134346CrossRefPubMed

51.

Navel V, Sapin V, Henrioux F, Blanchon L, Labbé A, Chiambaretta F, Baudouin C, Dutheil F (2022) Oxidative and antioxidative stress markers in dry eye disease: a systematic review and meta-analysis. Acta Ophthalmol 100:45–57. https://doi.org/10.1111/aos.14892CrossRefPubMed

52.

Cejková J, Ardan T, Jirsová K, Jechová G, Malec J, Simonová Z, Cejka C, Filipec M, Dotrelová D, Brunová B (2007) The role of conjunctival epithelial cell xanthine oxidoreductase/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjögren’s syndrome. Histol Histopathol 22:997–1003. https://doi.org/10.14670/HH-22.997CrossRefPubMed

53.

Cejková J, Ardan T, Simonová Z, Cejka C, Malec J, Dotrelová D, Brunová B (2008) Decreased expression of antioxidant enzymes in the conjunctival epithelium of dry eye (Sjögren’s syndrome) and its possible contribution to the development of ocular surface oxidative injuries. Histol Histopathol 23:1477–1483. https://doi.org/10.14670/HH-23.1477CrossRefPubMed

54.

Silvani L, Bedei A, De Grazia G, Remiddi S (2020) Arabinogalactan and hyaluronic acid in ophthalmic solution: experimental effect on xanthine oxidoreductase complex as key player in ocular inflammation (in vitro study). Exp Eye Res 196:108058. https://doi.org/10.1016/j.exer.2020.108058CrossRefPubMed

55.

Osei KA, Ovenseri-Ogbomo G, Kyei S, Ntodie M (2014) The effect of caffeine on tear secretion. Optom Vis Sci 91:171–177. https://doi.org/10.1097/OPX.0000000000000129CrossRefPubMed

56.

Park KY, Kim HJ, Ahn HS, Kim SH, Park EJ, Yim SY, Jun JB (2016) Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. Semin Arthritis Rheum 45:580–586. https://doi.org/10.1016/j.semarthrit.2016.01.003CrossRefPubMed

57.

Choi HK, Curhan G (2010) Coffee consumption and risk of incident gout in women: the Nurses’ health study. Am J Clin Nutr 92:922–927. https://doi.org/10.3945/ajcn.2010.29565CrossRefPubMedPubMedCentral

58.

Choi HK, Willett W, Curhan G (2007) Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum 56:2049–2055. https://doi.org/10.1002/art.22712CrossRefPubMed

59.

Guo H, Wang S, Peng H, Wang M, Li L, Huang J, Wu T (2023) Dose-response relationships of tea and coffee consumption with gout: a prospective cohort study in the UK Biobank. Rheumatology. https://doi.org/10.1093/rheumatology/kead019CrossRefPubMedPubMedCentral

60.

Choi HK, Curhan G (2007) Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 57:816–821. https://doi.org/10.1002/art.22762CrossRefPubMed

61.

Kela U, Vijayvargiya R, Trivedi CP (1980) Inhibitory effects of methylxanthines on the activity of xanthine oxidase. Life Sci 27:2109–2119. https://doi.org/10.1016/0024-3205(80)90492-0CrossRefPubMed

Title: Correlation between gout and dry eye disease
Authors: Tongtong Chen
Jiaqi Chen
Cong Zhao
Xiang Li
Publication date: 01-12-2024
Publisher: Springer Netherlands
Keywords: Gout
Xerophthalmia
Xanthine Alkaloid
Arthritis
Published in: International Ophthalmology / Issue 1/2024
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-02965-6

At a glance: The STEP trials

Springer Medicine

Correlation between gout and dry eye disease

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Objective demonstration of eyelid spasm relief with smartphone and custom software in hemifacial spasm patients

Cycle threshold values of SARS-CoV-2 RNA in conjunctival swabs and nasopharyngeal secretions: a comparative study from a tertiary care center in India

Evaluation of early period changes in intraocular pressure, ocular biometry and anterior segment after upper eyelid blepharoplasty

Evaluation of the relationship between tear meniscus changes and quality of life outcomes after external dacryocystorhinostomy

Corneal biomechanics and their association with severity of lens dislocation in Marfan syndrome

Impact of removing soft contact lenses 1 day versus 1 month before surgery on the outcomes of microkeratome laser in situ keratomileusis